Chiral Kinase Inhibitors

Title: Chiral Kinase Inhibitors

Volume: 11 Issue: 7

Author(s): Jian-kang Jiang, Min Shen, Craig J. Thomas and Mathew B. Boxer

Affiliation:

Keywords: Kinase inhibitors, chirality, P38a, AKT, Erk, Jak3, TrkA, optically active, cellular signaling pathways, stereocenter, chiral libraries, chronic myelogenous leukemia, obstructive pulmonary disease COPD, rheumatoid arthritis, Crohn's disease

Abstract: Small molecule kinase inhibitors are important tools for studying cellular signaling pathways, phenotypes and are, occasionally, useful clinical agents. With stereochemistry pervasive throughout the molecules of life it is no surprise that a single stereocenter can bestow a ligand with distinct binding affinities to various protein targets. While the majority of small molecule kinase inhibitors reported to date are achiral, a number of asymmetric compounds show great utility as tools for probing kinase-associated biomolecular events as well as promising therapeutic leads. The mechanism by which chirality is introduced varies but includes screening of chiral libraries, incorporation of chiral centers during optimization efforts and the rational installation of a chiral moiety as guided by structural and modeling efforts. Here we discuss several advanced chiral small molecule kinase inhibitors where stereochemistry plays an important role in terms of potency and selectivity.

Cite this article as:

Jiang Jian-kang, Shen Min, J. Thomas Craig and B. Boxer Mathew, Chiral Kinase Inhibitors, Current Topics in Medicinal Chemistry 2011; 11 (7) . https://dx.doi.org/10.2174/156802611795165052